Jeremy S Abramson

53PUBLICATIONS
265CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied statisticsLiquid biopsiesHaematological tumoursNumerical and computational mathematics not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (53)

|Jun 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

|Jun 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

|Jun 04, 2026
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL.

|Apr 27, 2026
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

|Feb 18, 2026
Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Manali Kamdar, Scott R Solomon, Jon E Arnason

|Dec 29, 2025
Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.

Jeremy S Abramson, David J Straus, Nancy L Bartlett

Pageof 9

Frequent Collaborators

8 joint publications

Jeffrey Barnes

8 joint publications

Jacob D Soumerai

6 joint publications

Matthew M Lei

6 joint publications

Ann Steward LaCasce